Cognitive Assessment for Stroke Patients: Reproductibility and Validity Study (Casper)

February 5, 2026 updated by: Centre Hospitalier Universitaire Dijon

After a CVA, all of the cognitive functions can be affected and analysed, but the presence of a language disorder may considerably hamper the evaluation of other functions.

The battery of rapid tests to screen for and quantify cognitive disorders, including the MMSE, the MOCA, the R-CAMCOG or the RBANS, are not suitable for aphasic patients because they contain items with a strictly verbal response. Because of this, inexperienced doctors cannot evaluate higher functions (other than language) of aphasics in routine practice. For the same reason, aphasics are regularly excluded from post-cva therapeutic protocols, whether or not the trial bears on the evolution of cognitive functions.

Nonetheless, it is possible to evaluate, at least roughly, all of the cognitive functions without resorting to language.

The investigator have developed , from validated tests and classical clinical manoeuvers, the Cognitive Assessment for Stroke Patients (CASP) :

  • for the rapid screening (less than 15 minutes) and quantification of post-cva cognitive disorders (6 functions: language, apraxia, short-term memory, temporal orientation, impaired spatial/visio-construction and executive functions);
  • the CASP can be used in most patients, including those with severe disorders of expression and moderate problems with comprehension, The format of these tests has been adapted so that severe disorders of expression (essentially left-hemisphere CVA), and left spatial impairment (right-hemisphere CVA) do not affect the ability to take the test. Its validity in terms of appearance and content were verified in 2011.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Actual)

263

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • France
      • Dijon, France, 21079
        • CHU de Dijon

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

For CVA patients

  • patients hospitalised in rehabilitation after a first recent hemispheric CVA (less than 6 weeks) ;
  • aged > 18;
  • absence of severe disorders of oral comprehension (BDAE aphasia severity score >2 for comprehension);
  • whatever the severity of oral expression disorders;
  • who have been given clear written and oral information, and after the doctor has verified their ability to understand the protocol.

For " Control " patients (to evaluate divergent validity)

  • patients hospitalised in rehabilitation units or geriatrics taking part in this study;
  • aged > 18.

Exclusion Criteria:

For CVA patients

  • patients who do not speak French;
  • cognitive disorders known before the CVA;
  • psychotic disorders known before the CVA;
  • major visual disorders incompatible with reading, known before the CVA.

For " Control " patients (to evaluate divergent validity)

  • patients who do not speak French;
  • cognitive disorders known before the CVA;
  • psychotic disorders known before the CVA;
  • major visual disorders incompatible with reading, known before the CVA.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Other
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Other: Cognitive Assessment
Other: Cognitive Assessment test

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
comprehensive assessment battery of higher functions
Time Frame: baseline
baseline
comprehensive assessment battery of higher functions
Time Frame: Evaluation at 3 ±1 days
Evaluation at 3 ±1 days
comprehensive assessment battery of higher functions
Time Frame: Evaluation at 6 ± 2 weeks
Evaluation at 6 ± 2 weeks
test of visual memory
Time Frame: baseline
baseline
test of visual memory
Time Frame: Evaluation at 3 ±1 days
Evaluation at 3 ±1 days
test of visual memory
Time Frame: Evaluation at 6 ± 2 weeks
Evaluation at 6 ± 2 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Centre Hospitalier Universitaire Dijon

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

January 2, 2015

Primary Completion (Actual)

March 29, 2019

Study Completion (Actual)

March 29, 2019

Study Registration Dates

First Submitted

July 12, 2013

First Submitted That Met QC Criteria

July 17, 2013

First Posted (Estimated)

July 22, 2013

Study Record Updates

Last Update Posted (Actual)

February 9, 2026

Last Update Submitted That Met QC Criteria

February 5, 2026

Last Verified

February 1, 2026

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • Benaim PHRC N 2012

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe